Does the media refer more to SYRE or BIIB?

In the previous week, Biogen had 33 more articles in the media than Spyre Therapeutics. MarketBeat recorded 36 mentions for Biogen and 3 mentions for Spyre Therapeutics. Biogen's average media sentiment score of 1.31 beat Spyre Therapeutics' score of 0.66 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 25 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SYRE or ALNY?

In the previous week, Alnylam Pharmaceuticals had 25 more articles in the media than Spyre Therapeutics. MarketBeat recorded 28 mentions for Alnylam Pharmaceuticals and 3 mentions for Spyre Therapeutics. Alnylam Pharmaceuticals' average media sentiment score of 0.98 beat Spyre Therapeutics' score of 0.66 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alnylam Pharmaceuticals 16 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SYRE or INSM more profitable?

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Spyre Therapeutics' return on equity of -30.74% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -30.74% -22.23% Insmed -76.94% -123.94% -44.30%

Does the media refer more to SYRE or INSM?

In the previous week, Spyre Therapeutics had 1 more articles in the media than Insmed. MarketBeat recorded 3 mentions for Spyre Therapeutics and 2 mentions for Insmed. Insmed's average media sentiment score of 0.84 beat Spyre Therapeutics' score of 0.66 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ROIV or SYRE?

In the previous week, Roivant Sciences had 17 more articles in the media than Spyre Therapeutics. MarketBeat recorded 20 mentions for Roivant Sciences and 3 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.66 beat Roivant Sciences' score of 0.25 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 10 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SYRE or MRNA?

In the previous week, Moderna had 120 more articles in the media than Spyre Therapeutics. MarketBeat recorded 123 mentions for Moderna and 3 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.66 beat Moderna's score of 0.37 indicating that Spyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 48 Very Positive mention(s) 20 Positive mention(s) 14 Neutral mention(s) 20 Negative mention(s) 16 Very Negative mention(s) Neutral

Spyre Therapeutics (SYRE) Competitors

$106.65 +0.16 (+0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$107.51 +0.86 (+0.81%)

As of 04:34 PM Eastern

Compare

SYRE vs. BIIB, ALNY, INSM, ROIV, and MRNA

Should you buy Spyre Therapeutics stock or one of its competitors? Spyre Therapeutics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Insmed (INSM), Roivant Sciences (ROIV), and Moderna (MRNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Spyre Therapeutics compare to Biogen?

Spyre Therapeutics (NASDAQ:SYRE) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Biogen has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Biogen	$9.89B	3.26	$1.29B	$5.65	38.61

Spyre Therapeutics presently has a consensus price target of $111.69, suggesting a potential upside of 4.73%. Biogen has a consensus price target of $227.07, suggesting a potential upside of 4.10%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Spyre Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

In the previous week, Biogen had 33 more articles in the media than Spyre Therapeutics. MarketBeat recorded 36 mentions for Biogen and 3 mentions for Spyre Therapeutics. Biogen's average media sentiment score of 1.31 beat Spyre Therapeutics' score of 0.66 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biogen	25 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 3.03, indicating that its stock price is 203% more volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Biogen has a net margin of 8.32% compared to Spyre Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Biogen	8.32%	11.18%	6.88%

80.4% of Spyre Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 15.7% of Spyre Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Biogen beats Spyre Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Spyre Therapeutics compare to Alnylam Pharmaceuticals?

Spyre Therapeutics (NASDAQ:SYRE) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Spyre Therapeutics' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Spyre Therapeutics has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

Spyre Therapeutics presently has a consensus target price of $111.69, suggesting a potential upside of 4.73%. Alnylam Pharmaceuticals has a consensus target price of $386.62, suggesting a potential upside of 63.82%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.96

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Alnylam Pharmaceuticals	$3.71B	8.50	$313.75M	$5.38	43.87

In the previous week, Alnylam Pharmaceuticals had 25 more articles in the media than Spyre Therapeutics. MarketBeat recorded 28 mentions for Alnylam Pharmaceuticals and 3 mentions for Spyre Therapeutics. Alnylam Pharmaceuticals' average media sentiment score of 0.98 beat Spyre Therapeutics' score of 0.66 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alnylam Pharmaceuticals	16 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alnylam Pharmaceuticals beats Spyre Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Insmed?

Spyre Therapeutics (NASDAQ:SYRE) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Spyre Therapeutics has a beta of 3.03, meaning that its stock price is 203% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Spyre Therapeutics has higher earnings, but lower revenue than Insmed. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Insmed	$606.42M	44.65	-$1.28B	-$4.11	N/A

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 1 more articles in the media than Insmed. MarketBeat recorded 3 mentions for Spyre Therapeutics and 2 mentions for Insmed. Insmed's average media sentiment score of 0.84 beat Spyre Therapeutics' score of 0.66 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics currently has a consensus price target of $111.69, indicating a potential upside of 4.73%. Insmed has a consensus price target of $205.52, indicating a potential upside of 65.77%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spyre Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Spyre Therapeutics' return on equity of -30.74% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Insmed	-76.94%	-123.94%	-44.30%

Summary

Spyre Therapeutics beats Insmed on 9 of the 16 factors compared between the two stocks.

How does Spyre Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Spyre Therapeutics (NASDAQ:SYRE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

In the previous week, Roivant Sciences had 17 more articles in the media than Spyre Therapeutics. MarketBeat recorded 20 mentions for Roivant Sciences and 3 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.66 beat Roivant Sciences' score of 0.25 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	10 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences currently has a consensus price target of $35.14, suggesting a potential downside of 3.37%. Spyre Therapeutics has a consensus price target of $111.69, suggesting a potential upside of 4.73%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Spyre Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.03, indicating that its stock price is 203% more volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Spyre Therapeutics has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Spyre Therapeutics	N/A	-30.74%	-22.23%

Spyre Therapeutics has lower revenue, but higher earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,179.61	-$299.77M	-$0.53	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A

Summary

Spyre Therapeutics beats Roivant Sciences on 10 of the 15 factors compared between the two stocks.

How does Spyre Therapeutics compare to Moderna?

Spyre Therapeutics (NASDAQ:SYRE) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Spyre Therapeutics has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-30.74%	-22.23%
Moderna	-141.43%	-28.30%	-19.39%

Spyre Therapeutics has a beta of 3.03, indicating that its share price is 203% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than Moderna. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A
Moderna	$2.21B	25.09	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 120 more articles in the media than Spyre Therapeutics. MarketBeat recorded 123 mentions for Moderna and 3 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.66 beat Moderna's score of 0.37 indicating that Spyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	48 Very Positive mention(s)	20 Positive mention(s)	14 Neutral mention(s)	20 Negative mention(s)	16 Very Negative mention(s)	Neutral

Spyre Therapeutics currently has a consensus price target of $111.69, indicating a potential upside of 4.73%. Moderna has a consensus price target of $74.31, indicating a potential downside of 46.50%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Spyre Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Spyre Therapeutics beats Moderna on 11 of the 16 factors compared between the two stocks.

Get Spyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYRE vs. The Competition

Export

Metric	Spyre Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.38B	$3.99B	$7.30B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-54.69	11.76	271.39	24.11
Price / Sales	N/A	1,296.80	604.56	77.78
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	14.79	17.27	11.18	6.40
Net Income	-$155.20M	-$22.72M	$3.46B	$348.28M
7 Day Performance	1.96%	2.83%	1.97%	0.95%
1 Month Performance	4.43%	9.67%	7.30%	5.15%
1 Year Performance	513.64%	54.74%	24.74%	16.18%

Spyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYRE Spyre Therapeutics	1.4685 of 5 stars	$106.65 +0.2%	$111.69 +4.7%	+512.7%	$9.38B	N/A	N/A	73
BIIB Biogen	3.9116 of 5 stars	$212.59 +1.6%	$227.07 +6.8%	+55.6%	$31.41B	$9.89B	37.63	7,500	Positive News
ALNY Alnylam Pharmaceuticals	4.8669 of 5 stars	$228.61 +1.8%	$393.86 +72.3%	-48.0%	$30.59B	$3.71B	42.49	2,770
INSM Insmed	3.3497 of 5 stars	$128.49 +0.1%	$205.52 +60.0%	-4.6%	$28.06B	$606.42M	N/A	1,664
ROIV Roivant Sciences	1.4965 of 5 stars	$37.37 +3.1%	$35.14 -6.0%	+204.5%	$26.99B	$8.26M	N/A	860	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SYRE) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyre Therapeutics (SYRE) Competitors

SYRE vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Spyre Therapeutics compare to Biogen?

Summary

How does Spyre Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Spyre Therapeutics compare to Insmed?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Summary

How does Spyre Therapeutics compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyre Therapeutics (SYRE) Competitors

SYRE vs. BIIB, ALNY, INSM, ROIV, and MRNA

How does Spyre Therapeutics compare to Biogen?

Which has stronger earnings & valuation, SYRE or BIIB?

Do analysts rate SYRE or BIIB?

Does the media refer more to SYRE or BIIB?

Which has more risk and volatility, SYRE or BIIB?

Is SYRE or BIIB more profitable?

Do institutionals & insiders hold more shares of SYRE or BIIB?

Summary

How does Spyre Therapeutics compare to Alnylam Pharmaceuticals?

Is SYRE or ALNY more profitable?

Which has more volatility & risk, SYRE or ALNY?

Do analysts prefer SYRE or ALNY?

Do insiders & institutionals hold more shares of SYRE or ALNY?

Which has stronger earnings and valuation, SYRE or ALNY?

Does the media favor SYRE or ALNY?

Summary

How does Spyre Therapeutics compare to Insmed?

Which has more risk & volatility, SYRE or INSM?

Which has higher earnings and valuation, SYRE or INSM?

Do institutionals & insiders believe in SYRE or INSM?

Does the media refer more to SYRE or INSM?

Do analysts prefer SYRE or INSM?

Is SYRE or INSM more profitable?

Summary

How does Spyre Therapeutics compare to Roivant Sciences?

Does the media prefer ROIV or SYRE?

Do analysts prefer ROIV or SYRE?

Which has more volatility & risk, ROIV or SYRE?

Do institutionals and insiders believe in ROIV or SYRE?

Is ROIV or SYRE more profitable?

Which has higher earnings and valuation, ROIV or SYRE?

Summary

How does Spyre Therapeutics compare to Moderna?

Is SYRE or MRNA more profitable?

Which has more risk & volatility, SYRE or MRNA?

Do insiders & institutionals believe in SYRE or MRNA?

Which has stronger valuation & earnings, SYRE or MRNA?

Does the media favor SYRE or MRNA?

Do analysts rate SYRE or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYRE vs. The Competition

Spyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools